Vascular Medicine
ReachMD
Episodes
Questions & Answers from the AHA 2023 Symposium
11/30/2023
Host: Manesh R. Patel, MD
Host: M. Cecilia Bahit, MD
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Duration:00:16:24
The Path Forward: What’s On The Horizon?
11/30/2023
Host: Manesh R. Patel, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Duration:00:16:24
While DOACs are Good for Some Things, They Are Not for Everyone
11/30/2023
Host: M. Cecilia Bahit, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Duration:00:12:29
While the DOAC Revolution Has Occurred, 40-50% of Patients Remain Untreated... Why?
11/30/2023
Host: Elaine Hylek, MD, MPH
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Duration:00:17:57
The DOAC Revolution: What Have We Learned?
11/30/2023
Host: Christopher B. Granger, MD
Anticoagulation has transformed the management of multiple potentially catastrophic disease states. Currently, available anticoagulation agents work on the common pathway of the coagulation cascade, inhibiting both thrombosis as well as hemostasis and increasing the risk of serious bleeding. Factor XIa inhibitors may completely change this anticoagulation landscape. Factor XIa affects the intrinsic thrombosis pathway, preserving the extrinsic and common pathways. Phase 2 data on multiple factor XIa inhibitors support a favorable safety profile for implementation, with reduced risk of bleeding being a consistent theme, for VTE prophylaxis, secondary stroke prevention in atrial fibrillation (AF), post-myocardial infarction (MI), and post-non-embolic stroke. This program explores novel factor XIa inhibitors currently under investigation and outlines anticoagulation’s exciting future.
Duration:00:23:57
Addressing Patient Management in ASCVD Risk Reduction: A Collaborative Approach
8/30/2023
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Charles P. Vega, MD
We now have evidence-based options to reduce atherosclerotic cardiovascular disease (ASCVD) event burden beyond any previously available therapy. A collaborative approach to addressing residual cardiovascular risk across a variety of risk factors that goes beyond LDL-C-lowering therapies is needed to optimally manage patients with or at high risk of ASCVD. Pharmacists treating these patients will benefit from a review of recent data and guidelines so they can incorporate these findings into clinical practice. Join us to ensure you’re keeping up with the science and giving your patients the best care.
Duration:00:48:14
Clinical and Practical Viability of RWE – What Now?
8/11/2023
Host: Craig I. Coleman, PharmD, FASHP
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:12:06
What Future Studies Are Out There on the Meaningfulness of Reversal in ICH?
8/11/2023
Host: Craig I. Coleman, PharmD, FASHP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:08:00
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for ICH?
8/11/2023
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:09:30
Meaningfulness of ISTH Chart Audit of In-hospital Mortality for GI Bleeds?
8/11/2023
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:08:38
Newest Emerging Data from ISTH: Andexanet Alfa vs. 4F-PCC?
8/11/2023
Host: Paul P. Dobesh, PharmD, FACC, FAHA, FCCP, BCPS, BCCP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:08:30
What’s the Best Available Evidence for Reversal of Life-Threatening Bleeds?
8/11/2023
Host: Craig I. Coleman, PharmD, FASHP
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:07:12
Anticoagulant-Associated Major Bleeding Is a Significant Problem: How Do I Address?
8/11/2023
Host: Deborah Siegal, MD, MSc, FRCPC
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:14:00
Setting the Stage: Case Considerations for Bleeding Management in Anticoagulated Patients
8/11/2023
Host: Jan Beyer-Westendorf, MD, PhD
The introduction and assessment of real-world data (RWD) associated with FXa inhibitor-related bleeds is of critical importance in treatment-emergent situations, as there has been limited information disseminated to date within the relatively complex clinical landscape. This program focuses on the role of reversal agents in the presence of life-threatening bleeds while on an anticoagulant. It covers the most recent key RWD published relative to the use of reversal or repletion strategies in anticoagulated patients.
Duration:00:09:30
What to Know About the No Surprises Act
12/21/2021
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Duration:00:10:29
Coping After COVID: How Can We Help Long-Haulers?
6/14/2021
Host: Andrew Wilner, MD, FACP, FAAN
Guest: William W. Li, MD
As the number of new COVID-19 infections continues to decrease and the United States begins to open back up, it’s important to note that there are patients who have survived COVID-19 but are still suffering. The newly coined term “COVID long-haulers” refers to those patients who continue to have symptoms even after the acute infection is resolved. Joining Dr. Andrew Wilner to share what we know so far about COVID long-haulers and how we can help them is vascular biologist Dr. William Li.
Duration:00:11:31
Navigating the Intersection of Antithrombotic Therapy & GI Bleeding
4/15/2021
Host: Peter Buch, MD, FACG, AGAF, FACP
Guest: Adam Olsen, MS, PA-C
Millions of patients are treated with anticoagulants, and many more are treated with antiplatelet therapy. But when those therapies overlap with GI bleeding, what do you need to know so that your patients don’t experience any problematic health outcomes? Dr. Peter Buch is discussing this topic with physician assistant Mr. Adam Olsen, who’s the Department Chair and Program Director for the Master of Physician Assistant Studies Program at Sacred Heart University in Stamford, Connecticut.
Duration:00:11:59
The Dangers of a Broken Heart: Collaborating on Cardiomyopathy
4/1/2021
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.
Duration:00:13:29
Seeking Out Symptoms of Broken Heart Syndrome
3/26/2021
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
With no standard criteria available, how do we detect broken heart syndrome in our patients? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, shares what we should be looking for.
Duration:00:05:59
An Epidemic Amid a Pandemic: CVD, COVID-19, & the Leading Cause of Death Worldwide
3/3/2021
Host: Matthew J. Sorrentino, MD, FACC, FASH
Guest: Salim S. Virani, MD, PhD, FACC, FAHA, FASPC
What is the leading cause of death worldwide? Dr. Matthew Sorrentino sits down with Dr. Salim Virani, who's a professor of medicine at Baylor College of Medicine in Houston, Texas, and the Cardiovascular Disease Fellowship director at Baylor, to discuss how the COVID-19 pandemic has impacted cardiovascular disease globally.
Duration:00:13:29